Pancreatic Cancer Research

ResearcherThe University of SydneyActive in the last 2 years

Mark P. Molloy

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-4679-5868; OpenAlex author ID A5069735960. Sources: OpenAlex.

Their work

Papers
3 (first author 0, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
9
Papers, trials and grants by year

2020: 1 paper · 2021: 1 paper · 2022: none · 2023: none · 2024: 1 paper

Papers 3

  1. Novel serum protein biomarker panel for early diagnosis of pancreatic cancer. Co-author DOI 10.1002/ijc.34928↗
  2. Data independent acquisition of plasma biomarkers of response to neoadjuvant chemotherapy in pancreatic ductal adenocarcinoma. Last author DOI 10.1016/j.jprot.2020.103998↗
  3. PSMD11, PTPRM and PTPRB as novel biomarkers of pancreatic cancer progression. Co-author DOI 10.1016/j.bbagen.2020.129682↗

Closest collaborators

The 9 strongest of 9 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Jaswinder Singh Samra · 3 shared papers, 2020–2024 · strength 0.53
  2. Sumit Sahni · 3 shared papers, 2020–2024 · strength 0.53
  3. Anubhav Mittal · 3 shared papers, 2020–2024 · strength 0.53
  4. Anthony James Gill · 2 shared papers, 2020–2024 · strength 0.35
  5. Sooin Byeon · 1 shared paper, 2024 · strength 0.24
  6. Matthew B. O’Rourke · 1 shared paper, 2021 · strength 0.17
  7. Sarah Maloney · 1 shared paper, 2020 · strength 0.11
  8. Josef Gillson · 1 shared paper, 2020 · strength 0.11
  9. Christopher Bahdah Nahm · 1 shared paper, 2020 · strength 0.11

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.